Assyro AI

Orange Book product · Brand (NDA)

TURALIO

PEXIDARTINIB HYDROCHLORIDE

Brand (NDA)NDA 211810RX DAIICHI SANKYO INC

At a glance

Oct 14, 2022

Approved

Brand (NDA)

Application

Not listed

TE code

12

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Oct 14, 2022

    3 yr 9 mo ago

  2. Today

  3. Exclusivity ends · ODE*

    FDA marketing exclusivity

    Aug 02, 2026

    in 1 mo

  4. Patent 8404700 expires

    Listed drug substance patent expiration.

    Nov 21, 2027

    in 1 yr 5 mo

  5. Patent 8722702 expires

    Listed drug substance patent expiration.

    Nov 21, 2027

    in 1 yr 5 mo

  6. Patent 9169250 expires

    Listed drug substance patent expiration.

    Nov 21, 2027

    in 1 yr 5 mo

  7. Patent 8461169 expires

    Listed method-of-use patent (U-2606) expiration.

    Apr 19, 2028

    in 1 yr 10 mo

  8. Patent 7893075 expires

    Listed drug substance patent expiration.

    May 04, 2033

    in 7 yr

  9. Patent 9358235 expires

    Listed method-of-use patent (U-2606) expiration.

    Jun 08, 2033

    in 7 yr 1 mo

  10. Patent 10189833 expires

    Listed method-of-use patent (U-2606) expiration.

    May 05, 2036

    in 10 yr

  11. Patent 10730876 expires

    Listed drug substance patent expiration.

    May 05, 2036

    in 10 yr

  12. Patent 9802932 expires

    Listed drug substance patent expiration.

    May 05, 2036

    in 10 yr

  13. Patent 10435404 expires

    Listed drug product patent expiration.

    Jul 24, 2038

    in 12 yr 3 mo

  14. Patent 10941142 expires

    Listed drug product patent expiration.

    Jul 24, 2038

    in 12 yr 3 mo

  15. Patent 10961240 expires

    Listed method-of-use patent (U-2606) expiration.

    Jul 24, 2038

    in 12 yr 3 mo

Pharmaceutical detail

Active ingredient

PEXIDARTINIB HYDROCHLORIDE

Strength

EQ 125MG BASE

Dosage form

CAPSULE

Route

ORAL

TE code

Not listed

Application

NDA 211810

Product number

002

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (1)

  • ODE*FDA marketing exclusivity

    Aug 02, 2026

    in 1 mo

Listed patents (12)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
8404700Nov 21, 2027in 1 yr 5 mo
Substance
8722702Nov 21, 2027in 1 yr 5 mo
Substance
9169250Nov 21, 2027in 1 yr 5 mo
Substance
8461169Apr 19, 2028in 1 yr 10 mo
U-2606
7893075May 04, 2033in 7 yr
Substance
9358235Jun 08, 2033in 7 yr 1 mo
U-2606
10189833May 05, 2036in 10 yr
U-2606
10730876May 05, 2036in 10 yr
Substance
9802932May 05, 2036in 10 yr
Substance
10435404Jul 24, 2038in 12 yr 3 mo
Product
10941142Jul 24, 2038in 12 yr 3 mo
Product
10961240Jul 24, 2038in 12 yr 3 mo
U-2606
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.